Most side-effect pages on this site start from a label, a trial or a set of adverse-event reports. For KPV there is none of the three, and the most useful document on the question is a record of what FDA looked for and did not find.
What KPV is, briefly
KPV is lysine-proline-valine, the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (molecular weight 342.43 g/mol per FDA's review). It is not a component of any approved drug, has no pharmacopoeial monograph and no adopted drug name. Research-market products sell it as injectable powder and oral capsules; the dose figures attached to them, and the absence of any origin for those figures, are on our KPV dosage page.
The search FDA ran, and what came back
FDA evaluated KPV free base and KPV acetate for its Pharmacy Compounding Advisory Committee meeting of 23–24 July 2026 (briefing document fda.gov/media/193346). Its human-safety section lists what was consulted — PubMed, Embase, FAERS, the Human Foods complaint system, ClinicalTrials.gov, professional bodies and clinical references — and reports the result item by item:
| What FDA looked for | Result |
|---|---|
| Clinical studies, any route | None |
| Human exposure data of any kind | None |
| Human pharmacokinetic or pharmacodynamic studies | None |
| FAERS reports and published case reports, through 3 Dec 2025 | None |
| Food, supplement and cosmetic complaints, 1 Jan 2004 – 3 Dec 2025 | No case in which KPV was administered |
| Animal acute toxicity, repeat-dose toxicity, genotoxicity, reproductive toxicity, carcinogenicity | None |
| Outsourcing-facility reports of compounding KPV, Jan 2017 – Jun 2025 | None |
Its conclusion: "FDA is particularly concerned about the lack of any human data on drug products containing these substances administered via any route of administration," and "potential safety risks associated with the use in humans are unknown."
We repeated the checks that can be repeated on 3 October 2026. openFDA's adverse-event endpoint returned no report naming KPV; ClinicalTrials.gov returned no study; PubMed returned 67 records with KPV in the title or abstract, none a clinical trial or a randomised study.
The route mismatch
The nomination FDA evaluated was for a 0.1% topical cream or gel, for wound healing and inflammatory skin conditions. The one physical-property finding that bears on safety concerns that route: in a human cadaver-skin study, KPV did not permeate well, which FDA said could limit systemic exposure from a cream — and could equally limit any effect.
The products sold to consumers are mostly injectable and oral. FDA's review records websites promoting KPV for inflammatory bowel disease, mast cell activation syndrome, histamine intolerance, COVID-19 recovery, Lyme disease, mould toxicity and pain syndromes. No route used commercially has any human data at all, and the one route that was formally proposed has none either.
Why melanotan's side effects are not a guide
KPV comes from the same hormone melanotan I and II imitate, so it is tempting to borrow their record. The laboratory work FDA cites argues against it: KPV "was unable to displace radiolabeled α-MSH binding" in rat brain tissue, mouse melanoma cells and MC1-receptor macrophages, and unlike alpha-MSH it did not increase cyclic AMP in MC1-receptor cells. Gene-knockout and blocking studies failed to show that MC2, MC3 or MC4 receptors carry KPV's anti-inflammatory effect in rodents; researchers have proposed NF-κB inhibition and uptake through the PepT1 transporter instead.
Melanotan's documented effects — darkened skin and moles, nausea, flushing — run through melanocortin receptors. On this evidence KPV should not be expected to share them. That is not a safety finding: a compound acting through different, poorly characterised pathways simply has a different set of unknowns.
The risks FDA named without data
With no human or toxicity data, FDA's safety discussion is about what could not be excluded:
- Immunogenicity and aggregation. FDA notes that peptides can trigger immune responses to themselves, that peptides as short as two amino acids have been shown to aggregate, and that aggregation increases immunogenicity risk. It found no study of either for KPV.
- Identity. "KPV" is used for the free base, the acetate salt and derivatives (one supplier lists a C-terminal amide, Lys-Pro-Val-NH2). FDA called inconsistent naming "a safety risk for patients as they may be dosed with a different BDS than the physician ordered."
- Impurities and microbiology. The certificate of analysis supplied with the nomination contained no microbiological testing, and no published source characterised individual impurities or peptide aggregates. FDA found both KPV forms "not well-characterized."
How purity and identity are tested, and what a certificate does not show, is covered on our peptide testing page.
KPV inside blends
Most KPV sold today is not sold alone: it is the fourth component of the KLOW blend, alongside GHK-Cu, BPC-157 and TB-500. In a premixed vial every draw delivers KPV at a fixed ratio to the others, so a reaction cannot be attributed to it. That record is on our KLOW and GLOW side-effects page.
Reading this record
"No side effects reported" is accurate and means almost nothing here: there are no reports because there are no studies, no approved product and no pharmacy reporting. The finding is the absence, documented by the regulator and repeated on 3 October 2026. What KPV is and where it comes from is in Peptide Lexicon's KPV entry; why low report counts for research compounds are uninformative is on our peptide side-effects overview. Anyone who has used KPV and has symptoms should tell a doctor what the label said and where it was bought.
Sources and dates
- FDA briefing document, Pharmacy Compounding Advisory Committee, 23–24 July 2026: KPV-related bulk drug substances (fda.gov/media/193346) — characterisation, historical use, nonclinical assessment, human safety and conclusion sections, read 2026-10-03.
- FDA. Certain bulk drug substances for use in compounding that may present significant safety risks, KPV entry, content current as of 2026-04-22, read 2026-10-03.
- openFDA drug adverse-event endpoint, medicinal product "KPV", read 2026-10-03 (no match).
- ClinicalTrials.gov v2 API, term "KPV", read 2026-10-03 (0 studies).
- PubMed E-utilities, KPV[tiab] (67 records), KPV[tiab] with clinical-trial or randomised filters (0), read 2026-10-03.
Corrections go to the contact page.